Jan–Mar 2022 • Vol LXI • No. 3 5 Septilin® in the Management of Upper Respiratory Tract Infections An excerpt of the clinical study conducted by Nigam P et al published in The Medicine & Surgery is featured here. This study enrolled 150 patients (mean age, 30.6 ± 8.6 y; male:female ratio, 2.1:1) with upper respiratory tract infections (URTIs). A detailed medical history of all the patients was obtained, and they were subjected to routine blood tests for hemoglobin, total and differential leukocyte counts, and erythrocyte sedimentation rate. A leukocyte count up to 12,000/mm3 with evidence of slight toxemia differentiated the mild from the severe grade of infection. Patients with mild infections were given Septilin, at a dosage of 1 tablet, TID, and those with severe infection were given, 2 tablets, TID, for 2 to 3 weeks. The therapeutic response was evaluated as good, fair, or poor from days 3 to 5 in acute cases and from days 14 to 21 in chronic cases. The clinical improvement was assessed based on the degree of resolution of inflammation; relief from pain, tenderness, and other symptoms; and normalization of leukocyte count. Results showed that Septilin is effective in controlling acute and chronic URTIs. The overall therapeutic response was 92%. Septilin was found to be most effective in rhinitis with nasal obstruction (100%), acute laryngitis (100%), tracheobronchitis (100%), and acute tonsillitis (100%). In 12 cases, where the therapeutic response was initially poor, Septilin acted as a good adjuvant to antibiotics, and patients soon responded to the combination of antibiotics with Septilin. There was no adverse effect due to Septilin. Patients who experienced recurrence showed varying degrees of improvement after re-treatment with Septilin; there was no resistance to Septilin with prolonged treatment. Thus, Septilin is effective and safe in the treatment of acute and chronic URTIs. Septilin® (SYRUP, TABLET) Builds the body’s own defense mechanism Septilin, a phytopharmaceutical formulation, is recommended for the treatment and management of various infections and prevention of their recurrence. The immunomodulatory action of Septilin potentiates the immune responses of the body. Septilin also reduces inflammation and allergy and corrects the underlying pathologic features associated with recurrent infections. Septilin is a valuable adjuvant in infection management, as it builds the body’s own defense mechanism. When coprescribed with antibiotics, Septilin ensures faster recovery and prevents recurrence. Septilin provides excellent short- and long-term safety. Clinical Evidence 1 An excerpt of the clinical study conducted by Rahman H published in Probe is featured here. This study enrolled 42 patients (32 males and 10 females) with recurrent URTIs, such as chronic tonsillitis, laryngitis, pharyngitis, and sinusitis, that were resistant to earlier treatments with antibiotics, antiallergics, and anti-inflammatory drugs. The dosage of Septilin syrup was as follows: patients aged up to 2 years, ½ teaspoon, TID, and < 2 years, 1 teaspoonful, TID. Septilin tablets were given to patients > 6 years at a dosage of 1 tablet, TID. Six weeks’ treatment was advised in all cases; 66.7% completed the course, while 14.2% took the treatment for < 4 weeks. The results of the treatment with Septilin were good (long-term subjective and objective relief ) in 59.5% cases and fair (frequency of relapses reduced significantly) in 28.6% (Table). There was long-term subjective and objective relief with a significant reduction in the frequency of relapses in as many as 37 (88%) patients. No recurrence or side effects were seen during follow-up. Thus, this study proves that both the syrup and the tablet forms of Septilin are equally effective in the management of URTIs. Clinical Evidence 2 Table. Response to Septilin Therapy Condition Form of Medication Response to Treatment Total Good Fair Poor Recurrent URTI Syrup 18 5 4 27 Tablets 1 1 — 2 Chronic Tonsillitis Syrup 2 1 — 3 Tablets 4 3 1 8 Chronic Pharyngitis Syrup — 1 — 1 Tablets — — — — Chronic Sinusitis Syrup — — — — Tablets – 1 — 1 Total, n (%) 25 (59.5) 12 (28.6) 5 (11.9) 42 URTI, upper respiratory tract infection.
RkJQdWJsaXNoZXIy OTU3ODk=